GENFIT obtains non-dilutive financing of 11 million euros in the form of a loan guaranteed by the State


Lille, France; Cambridge, MichiganA; June 24, 2021GENFIT (Nasdaq and Euronext: GNFT), an advanced-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and hepatic diseases, today announced the securing of a non-dilutive loan of 11 million euros guaranteed by the French government (known under the name of State Guaranteed Loan or State guaranteed loan in French).

The loan, granted in the context of the COVID-19 pandemic by a syndicate of French banks, is 90% guaranteed by the French state with an initial term of one year with repayment options of up to six years.

Pascal Prigent, CEO of GENFIT, commented : “GENFIT thanks the French government for creation this funding mechanism as good as partner banks for thetheir support: BNP Paribas, Natixis, CIC Nord Ouest and Crédit du Nord. This loan contributes to enhancement our financial visibility and allowing us to stay fully engaged at execution of our strategy. I would also like to take this opportunity remind our shareholders that we are countis lying on their support at meet the quorum at the Extraordinary General Meeting of June 30, 2021 – whose purpose will be allow GENFIT to have the tools to accelerate the renewal of the Company strategy. “


GENFIT is an advanced stage biopharmaceutical company dedicated to improving the lives of patients with cholestatic and metabolic chronic liver disease. GENFIT is a pioneer in the field of nuclear receptor drug discovery, with a rich history and a strong scientific heritage spanning more than two decades. GENFIT is currently enrolled in ELATIVE ™, a Phase 3 clinical trial evaluating elafibranor in patients with Primary Biliary Cholangitis (PBC). Elafibranor is an investigational compound that has not been reviewed and has not received regulatory approval. As part of GENFIT’s global approach to the clinical management of patients with liver disease, the Company is also developing NIS4®, a new non-invasive blood diagnostic technology that could allow easier identification of patients. with at-risk NASH. In January 2019, GENFIT signed a license agreement with Labcorp® to make NIS4® technology available for use in clinical research through its drug development subsidiary, Covance. In September 2020, GENFIT signed another license agreement with Labcorp to commercialize NIS4® in the United States and Canada as a laboratory developed test. Since April 2021, Labcorp has been marketing NASHnext ™, optimized by NIS4®, for clinical use. GENFIT also continues to explore the opportunities to obtain a formal MA for a in vitro diagnosis (IVD) supported by NIS4® technology. For more information, please visit: GENFIT has offices in Lille and Paris, France, and Cambridge, MA, USA. GENFIT is a company listed on the Nasdaq Global Select Market and on compartment B of the regulated market of Euronext in Paris (Nasdaq and Euronext: GNFT).


This press release contains certain forward-looking statements regarding GENFIT, including those within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the financing of the Company. The use of certain words, including “consider”, “contemplate”, “think”, “aim”, “expect”, “understand”, “should”, “aspire”, “estimate”, “believe” “,” Wish “,” may “,” could “,” allow “,” seek “,” encourage “or” have confidence “or (as the case may be) the negative forms of these terms or any other variation of these terms or other similar terms their meaning is intended to identify forward-looking statements. Although the Company believes that its projections are based on the reasonable expectations and assumptions of the management of the Company, these forward-looking statements are subject to numerous known and unknown risks and uncertainties, which could cause actual results to differ materially. of those expressed, implied or proposed by forward-looking statements. These risks and uncertainties include, among others, the uncertainties inherent in research and development, including with respect to the safety, biomarkers, progress and results of its ongoing and planned clinical trials, review and outcomes. regulatory approvals of its drug and diagnostic candidates, fluctuations in currency exchange rates and the Company’s continued ability to raise capital to finance its development, as well as the risks and uncertainties discussed or identified in the Company’s public documents with the French authorities Aauthority of Marchas Financial, including those listed in chapter 2 “Main risks and uncertainties” of the Company’s 2020 Universal Registration Document filed with the AMF on April 23, 2021 under number D.21-0350, available on the website of the Company ( and on the AMF website ( and public documents and reports filed with the United States Securities and Exchange Commission (“SEC”), including the 2020 Annual Report of the Company on Form 20-F filed with the SEC on April 23, 2021. Further, although the results, performance, financial condition and liquidity of the Company, as well as the development of the industry in which it operates comply with these forward-looking statements, they may not be predictive of results or developments in future periods. These forward-looking statements speak only as of the date of publication of this document. Except as required by applicable law, the Company does not undertake any obligation to update or revise any information or forward-looking statement, whether as a result of new information, future events or otherwise.


GENFIT | Investors

Phone. : +1 (617) 714 5252 | [email protected]


Stéphanie Boyer – Press relations | Phone: +333 2016 4000 | [email protected]

GENFIT | 885 Avenue Eugène Avinée, 59120 Loos – FRANCE | +333 2016 4000 |


Leave A Reply

Your email address will not be published.